Anasec 40 mg/vial (IV Injection)
40 mg vial: ৳ 70.21
Medicine Details
Category | Details |
---|---|
Generic | Omeprazole |
Company | Novo healthcare and pharma ltd |
Also available as |
Indications
- Gastric and duodenal ulcer
- NSAID-associated duodenal and gastric ulcer
- Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
- Gastro-esophageal reflux disease
- Long-term management of acid reflux disease
- Acid-related dyspepsia
- Severe ulcerating reflux esophagitis
- Prophylaxis of acid aspiration during general anesthesia
- Zollinger-Ellison syndrome
- Helicobacter pylori-induced peptic ulcer
Pharmacology
- Inhibitor of gastric acid secretion
- Blocks hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
- Onset of antisecretory effect within one hour
- Maximum effect occurring within two hours
- Inhibition of secretion lasting up to 72 hours
- Gradual return of secretory activity over 3 to 5 days upon discontinuation
Dosage
- Dosage for benign gastric and duodenal ulcer
- Dosage for NSAID-associated duodenal or gastric ulcer
- Dosage for gastro-esophageal reflux disease
- Dosage for long-term management of acid reflux disease
- Dosage for acid-related dyspepsia
- Dosage for prophylaxis of acid aspiration
- Dosage for Zollinger-Ellison syndrome
- Dosage for Helicobacter pylori eradication regimen in peptic ulcer disease
- Pediatric dosage in severe ulcerating reflux esophagitis
Administration
- Directions for use of IV Injection
- Directions for use of IV Infusion
- Instructions for intravenous administration only
- Reconstitution guidelines for IV injection
- Guidelines for IV infusion over a period of 20-30 minutes or more
- Preparation of IV solution using saline or 5% Dextrose for infusion
- Precautions for not mixing with other drugs in the same infusion set
Interaction
- Impact on absorption of ketoconazole
- Metabolism through cytochrome P450 affecting elimination of diazepam, phenytoin, and warfarin
- Monitoring of patients receiving warfarin or phenytoin
- Potential changes in blood concentration of phenytoin and coagulation time with concurrent treatment
- Increased plasma concentrations during coadministration with clarithromycin
- No evidence of interaction with phenacetin, theophylline, caffeine, etc.
- Increased bioavailability of digoxin with simultaneous treatment
Contraindications
- Known hypersensitivity to omeprazole
- Need to exclude possibility of malignancy before treatment
Side Effects
- Mild and reversible adverse reactions
- Reports of skin rash, urticaria, and pruritus
- Occasional cases of atrophic gastritis
- Gastrointestinal reactions including diarrhea, nausea/vomiting, flatulence, and abdominal pain
- Isolated cases of paraesthesia, dizziness, and insomnia
- Reports of reversible mental confusion, agitation, and depression
- Cases of arthritic and myalgic symptoms
- Occasional reports of blurred vision, taste disturbance, and peripheral edema
Pregnancy & Lactation
- No adverse effects on pregnancy or newborn health based on prospective studies
- Use during pregnancy
- No information available on passage into breast milk
- Discontinuation of breastfeeding if essential use is considered
Precautions & Warnings
- Avoid concomitant use with clopidogrel
- Possible association with increased risk for osteoporosis-related fractures
- Occasional presence of atrophic gastritis in long-term use
- Potential for methotrexate toxicities with concomitant use
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children